aTyr Pharma (ATYR) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scilex (SCLX) has outperformed aTyr Pharma (ATYR) over the past year, losing 73.0% versus a loss of 74.5%. Over five years, ATYR leads with a -97.1% price change compared with -98.6% for SCLX. aTyr Pharma is the larger company by market cap ($24.9 million vs $21.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | SCLX |
|---|---|---|
| Share price | $0.254 | $3.10 |
| Market cap | $24.91M | $21.81M |
| 1-day change | -0.51% | +4.73% |
| YTD return | -67.39% | -61.03% |
| 1-year return | -74.47% | -72.96% |
| 5-year return | -97.07% | -98.65% |
| Forward P/E | — | 4.25 |
| EPS (TTM) | $-0.62 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $16.81 |
| 52-week low | $0.25 | $2.62 |
| Distance from 52-week high | -77.32% | -81.56% |
| Analyst consensus | buy | — |
| Avg. price target upside | +1025.98% | — |
| Average volume | 3.24M | 54.58K |
| Shares outstanding | 98.09M | 7.03M |
| Employees | 58 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
ATYR vs SCLX FAQ
Which is bigger, aTyr Pharma or Scilex?
aTyr Pharma (ATYR) is larger, with a market capitalization of $24.91M compared with $21.81M for Scilex (SCLX).
Which stock has performed better over the past year, ATYR or SCLX?
SCLX returned -72.96% over the past 12 months, compared with -74.47% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.